Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GCC 1366: Neoadjuvant Aromatase Inhibitors in Obese and Overweight Breast Cancer Patients
NCT02095184Terminated
- Sponsor
- University of Maryland, Baltimore
- Start
- May 2015
- Primary completion
- Jul 2024
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of anastrozole and letrozole in breast cancer (6 cohorts), sponsored by University of Maryland, Baltimore. Primary endpoint: Percent Change in Proliferative Index (Ki67). Started May 2015; status: terminated.
02
Drugs
anastrozoleletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02095184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02095184.